BD Headquarters / Image: Kristoffer Tripplaar
A recent Reuters article announced Becton Dickinson’s acquisition of CR Bard. The $24 billion dollar deal, consisting of cash and stock, aims to expand Becton’s focus beyond diabetes to include vascular disease, urology, hernia, and cancer. This is the latest in medical M&A trend likely caused by an overall decrease in revenue growth, healthcare provider consolidation, and pressure from healthcare payers to decrease treatment costs.
The deal is expected to close in the fall of 2017, assuming it receives regulatory and shareholder approval.
Companies in this article
